https://www.relmada.com/product-development
REL-1017 is in Phase 3 trials now. It is focusing on brain hyperexcitability. We all know that's a major factor in tinnitus.
This drug doesn't belong in the Research News forum since it has no focus on tinnitus, but for those with reactive tinnitus, this might be another treatment.
REL-1017's goal is to promote BDNF and block the NMDAR channel. This seems very promising for Major Depressive Disorder, but the neuronal actions seem related to our condition.
REL-1017 is in Phase 3 trials now. It is focusing on brain hyperexcitability. We all know that's a major factor in tinnitus.
This drug doesn't belong in the Research News forum since it has no focus on tinnitus, but for those with reactive tinnitus, this might be another treatment.
REL-1017's goal is to promote BDNF and block the NMDAR channel. This seems very promising for Major Depressive Disorder, but the neuronal actions seem related to our condition.
